Sunday 18 October 2026
Export LENZ’s income statement to Excel — free account
LENZ Therapeutics, Inc.
LENZ Healthcare Biotechnology
LENZ Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $19.1 million. In the quarter to June 2026, revenue grew 9.72%, EPS fell 92.5% and free cash flow fell 229.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.27
0.30
−8.40%
Follow LENZ
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.30 | 13.67 | 0.00 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.60) | (8.54) | (13.96) | (154.80) | |
P/B ratio |
0.81 | 1.16 | 1.62 | 6.86 | |
Price to Tangible BV |
0.81 | 1.16 | 1.62 | 6.86 | |
EV/Sales |
(1.84) | 1.46 | 0.00 | 0.00 | |
EV/EBITDA |
0.29 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
0.35 | (0.35) | (2.47) | (24.98) | |
EV/FCF |
0.35 | (0.35) | (2.44) | (24.47) | |
Quick Ratio |
12.81 | 10.03 | 13.81 | 12.39 | |
Current Ratio |
13.55 | 10.40 | 14.23 | 12.69 | |
Net Debt/EBITDA |
6.46 | 5.87 | 7.62 | 10.78 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.09 | 0.09 | 0.00 | 0.00 | |
Operating CF/Net income |
1.21 | 0.81 | 0.92 | 0.51 | |
Capex/Depreciation |
(0.15) | (0.16) | (0.36) | (3.51) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 30.33% | |
Selling, General and Administrative Expense of Revenue |
717.79% | 2,365.07% | 2,495.78% | 220.77% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
81.52% | 227.20% | 231.61% | 27.75% | |
Graham Net Nets |
1.21 | 0.84 | 0.61 | 0.14 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(72.01%) | (39.34%) | (17.56%) | (4.53%) | |
Free Cash Flow Yield |
(64.21%) | (30.48%) | (15.18%) | (3.47%) | |
Revenue per Share |
0.17 | 0.06 | 0.06 | 0.44 | |
Operating CF per Share |
(1.23) | (1.07) | (1.15) | (0.30) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Free Cash Flow per Share |
(1.23) | (1.07) | (1.15) | (0.32) | |
Cash per Share |
7.01 | 8.24 | 10.15 | 7.08 | |
Shareholders Equity per Share |
6.99 | 7.86 | 9.87 | 6.79 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.99 | 7.86 | 9.87 | 6.79 | |
Free Cash Flow |
(38.73) | (33.60) | (33.06) | (9.03) | |
Working Capital |
216.07 | 242.56 | 280.23 | 190.68 | |
Capital Expenditures |
(0.02) | (0.02) | (0.04) | (0.44) | |
Net Current Asset Value |
215.95 | 242.32 | 279.88 | 190.22 | |
EV/EBIT |
0.29 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.02 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
4.75 | 7.30 | 4.21 | 3.54 | |
Average Assets |
226.96 | 236.89 | 260.59 | 217.36 | |
Average Common Equity |
212.81 | 219.25 | 244.21 | 204.60 |
Columns are period end dates